Amg National Trust Bank Incyte Corp Transaction History

Amg National Trust Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$67.18 - $84.11 $11,219 - $14,046	-167 Reduced 1.46%	11,269 $905,000
Q3 2022 Nov 03, 2022	SELL	$66.18 - $82.86 $727 - $911	-11 Reduced 0.1%	11,436 $763,000
Q2 2022 Aug 05, 2022	BUY	$66.18 - $83.18 $59,959 - $75,361	906 Added 8.6%	11,447 $870,000
Q1 2022 May 10, 2022	BUY	$66.02 - $79.71 $59,418 - $71,739	900 Added 9.34%	10,541 $837,000
Q4 2021 Feb 04, 2022	BUY	$63.34 - $74.11 $16,785 - $19,639	265 Added 2.83%	9,641 $708,000
Q3 2021 Oct 28, 2021	SELL	$68.67 - $84.02 $25,682 - $31,423	-374 Reduced 3.84%	9,376 $645,000
Q2 2021 Aug 03, 2021	BUY	$79.87 - $87.53 $778,732 - $853,417	9,750 New	9,750 $820,000

707

189M

909K

489K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Amg National Trust Bank, based on Form 13F filings with the SEC.

Stay updated on Amg National Trust Bank with notifications on news.